Pipeline

SPV’s pipeline is intentionally focused on next-generation CDK programs engineered to address resistance, durability, and safety, with translational relevance incorporated from the outset.

1. CDK 4/6/9 Inhibitor Program

SPV Therapeutics’ flagship CDK4/6/9 program is a next-generation approach designed to address adaptive resistance that limits first-generation CDK4/6 inhibitors. By integrating balanced inhibition of CDK4, CDK6, and CDK9, the program targets both cell-cycle control and transcriptional dependencies. The enantiopure, orally bioavailable small-molecule platform is development-ready, supported by scalable chemistry, backup and follow-on molecules, and exploration of emerging modalities. Preclinical activity has been observed across RB-positive and RB-negative models, including aggressive subtypes such as TNBC.

Additional Preclinical Programs:

2. PROTAC CDK Degraders
Targeted CDK degradation strategy with a lead molecule, proof-of-concept data, follow-on libraries, and patent-ready IP.

3. Selective CDK9 Inhibitors
Transcription-focused inhibitors addressing oncogenic dependency and resistance, supported by lead compounds, proprietary libraries, and issued and pending IP.

4. Selective CDK4 Inhibitors
Enantiopure CDK4 inhibitors designed to improve safety and durability, with validated leads, backup compounds, scalable synthesis, and patent-ready IP.

All programs are preclinical and described for scientific and informational purposes only.